Top

Published in:

01-09-2016 | Original Article

MicroRNA-125b promotes invasion and metastasis of gastric cancer by targeting STARD13 and NEU1

Authors: Shuai Chang, Shicai He, Guanglin Qiu, Jing Lu, Jin Wang, Junsong Liu, Lin Fan, Wei Zhao, Xiangming Che

Published in: Tumor Biology | Issue 9/2016

Abstract

MicroRNAs have been documented playing key roles in cancer development and progression. Here, we investigate the role of miR-125b in gastric cancer metastasis. We found that the expression of miR-125b was up-regulated in gastric cancer tissue specimens compared with their corresponding nontumorous tissues, and the up-regulated miR-125b level was significantly associated with TNM stage and lymph node-metastasis. Overexpression of miR-125b promoted gastric cancer cell migration and invasion in vitro and metastasis in vivo. STARD13 and NEU1 were identified as direct target genes of miR-125b by luciferase assays, and they were involved in the cell migration and invasion regulated by miR-125b in gastric cancer. Taken together, miR-125b functions as an oncogene in gastric cancer and represents a new potential therapeutic target for gastric cancer.

Available only for authorised users

Jemal A, Forman D, Bray F, Center MM, Ferlay J, Ward E. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed

Coburn NG. Lymph nodes and gastric cancer. J Surg Oncol. 2009;99(4):199–206.CrossRefPubMed

Shi Y, Zhou Y. The role of surgery in the treatment of gastric cancer. J Surg Oncol. 2010;101(8):687–92.CrossRefPubMed

Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–8.CrossRefPubMed

Karnoub AE, Dash AB, Vo AP, Andrew S, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63.CrossRefPubMed

Hanyu A, Kojima KK. Functional in vivo optical imaging of tumor angiogenesis, growth, and metastasis prevented by administration of anti-human vegf antibody in xenograft model of human fibrosarcoma Ht1080 cells. Cancer Sci. 2009;100(11):2085–92.CrossRefPubMed

Zhang Z, Liu X, Feng B, Liu N, Wu Q, Han Y, et al. STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer. Oncogene. 2015;34:4808–20.CrossRefPubMed

Xing F, Sharma S, Liu Y, Mo Y-Y, Wu K, Zhang Y-Y, et al. miR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-|[alpha]. Oncogene. 2015;4:4890–900.CrossRef

Zhang S, Zhang C, Liu W, Zheng W, Zhang Y, Wang S, et al. MicroRNA-24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3. Int J Oncol. 2015;47:1351–60.PubMed

10.

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRefPubMed

11.

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8. doi:10.1038/nature03702.CrossRefPubMed

12.

Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(29):4677–84. doi:10.1200/jco.2005.05.5194.CrossRef

13.

Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. New Engl J Med. 2005;353(17):1793–801. doi:10.1056/NEJMoa050995.CrossRefPubMed

14.

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189–98. doi:10.1016/j.ccr.2006.01.025.CrossRefPubMed

15.

Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. J Am Med Assoc. 2007;297(17):1901–8. doi:10.1001/jama.297.17.1901.CrossRef

16.

Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. J Am Med Assoc. 2008;299(4):425–36. doi:10.1001/jama.299.4.425.CrossRef

17.

Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183–9. doi:10.1182/blood-2007-07-098749.CrossRefPubMedPubMedCentral

18.

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.CrossRefPubMed

19.

Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69. doi:10.1038/nrc1840.CrossRefPubMed

20.

Van SE, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 2015;17(1):1–15.CrossRef

21.

Krishnan P, Ghosh S, Wang B, Li D, Narasimhan A, Berendt R, et al. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. BMC Genomics. 2015;16.

22.

Jun-Nian Z, Quan Z, Hai-Yang W, Biao Z, Si-Ting L, Xue N, et al. MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. Hepatology. 2015;62:801–15.CrossRef

23.

Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13(3):272–86. doi:10.1016/j.ccr.2008.02.013.CrossRefPubMed

24.

Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(24):7574–83. doi:10.1158/1078-0432.ccr-11-1714.CrossRef

25.

Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11(2):136–46. doi:10.1016/s1470-2045(09)70343-2.CrossRefPubMed

26.

Guan Y, Yao H, Zheng Z, Qiu G, Sun K. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer. 2011;128(10):2274–83. doi:10.1002/ijc.25575.CrossRefPubMed

27.

Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer. 2011;128(8):1758–69. doi:10.1002/ijc.25509.CrossRefPubMed

28.

Liang L, Wong CM, Ying Q, Fan DN, Huang S, Ding J, et al. MicroRNA-125b suppressed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology. 2010;52(5):1731–40. doi:10.1002/hep.23904.CrossRefPubMed

29.

Kappelmann M, Kuphal S, Meister G, Vardimon L, Bosserhoff AK. MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. Oncogene. 2013;32(24):2984–91. doi:10.1038/onc.2012.307.CrossRefPubMed

30.

Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011;71(10):3552–62. doi:10.1158/0008-5472.can-10-2435.CrossRefPubMed

31.

Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A. 2007;104(50):19983–8. doi:10.1073/pnas.0706641104.CrossRefPubMedPubMedCentral

32.

Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate. 2011;71(5):538–49. doi:10.1002/pros.21270.CrossRefPubMed

33.

Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682–8. doi:10.1038/nature06174.CrossRefPubMed

34.

Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12(3):247–56. doi:10.1038/ncb2024.PubMedPubMedCentral

35.

Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP. TGF-beta upregulates miR-181a expression to promote breast cancer metastasis. J Clin Inves. 2013;123(1):150–63. doi:10.1172/jci64946.CrossRef

36.

Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010;6(3):e1000879. doi:10.1371/journal.pgen.1000879.CrossRefPubMedPubMedCentral

37.

Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H, et al. Serum miR-21, miR-29a and miR-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin Cancer Res. 2015;21:4234–42.CrossRefPubMedPubMedCentral

38.

Li J, You T, Jing J. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway. Cell Prolif. 2014;47(2):152–60.CrossRefPubMed

39.

Mark B, Frankel WL, Fabio P, Stefano V, Hansjuerg A, Hagan JP, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA J Am Med Assoc. 2007;297(17):1901–8.CrossRef

40.

Nelson PT, Baldwin DA, Kloosterman WS, Plasterk RH, Mourelatos Z. RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. Rna Publ Rna Soc. 2006;12(2):187–91.CrossRef

41.

Song F, Yang D, Liu B, Guo Y, Zheng H, Li L, et al. Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(4):878–89. doi:10.1158/1078-0432.ccr-13-1844.CrossRef

42.

Wu JG, Wang JJ, Jiang X, Lan JP, He XJ, Wang HJ, et al. MiR-125b promotes cell migration and invasion by targeting PPP1CA-Rb signal pathways in gastric cancer, resulting in a poor prognosis. Gastric Cancer Offi J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2015;18(4):729–39. doi:10.1007/s10120-014-0421-8.

43.

Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, et al. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res MCR. 2011;9(7):824–33. doi:10.1158/1541-7786.mcr-10-0529.CrossRefPubMed

44.

Nadine R, Hellmuth-Alexander M, Monika J, Hans-Joachim M, Ina W, Kurt M, et al. Reference miRNAs for miRNAome analysis of urothelial carcinomas. PLoS One. 2012;7(6):e39309.CrossRef

45.

Rittinger K, Walker PA, Eccleston JF, Nurmahomed K, Owen D, Laue E, et al. Crystal structure of a small G protein in complex with the GTPase-activating protein rhoGAP. Nature. 1997;388(6643):693–7. doi:10.1038/41805.CrossRefPubMed

46.

Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY, et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem. 2003;278(12):10824–30. doi:10.1074/jbc.M208310200.CrossRefPubMed

47.

Leung TH, Ching YP, Yam JW, Wong CM, Yau TO, Jin DY, et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci U S A. 2005;102(42):15207–12. doi:10.1073/pnas.0504501102.CrossRefPubMedPubMedCentral

48.

Kawai K, Seike J, Iino T, Kiyota M, Iwamae Y, Nishitani H, et al. START-GAP2/DLC2 is localized in focal adhesions via its N-terminal region. Biochem Biophys Res Commun. 2009;380(4):736–41. doi:10.1016/j.bbrc.2009.01.095.CrossRefPubMed

49.

Khalil BD, Hanna S, Saykali BA, El-Sitt S, Nasrallah A, Marston D, et al. The regulation of RhoA at focal adhesions by StarD13 is important for astrocytoma cell motility. Exp Cell Res. 2014;321(2):109–22.CrossRefPubMed

50.

Xiaorong L, Wei W, Liyuan Q, Kaiyan Y. Underexpression of deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma. BMC Cancer. 2008;8:205. doi:10.1186/1471-2407-8-205.CrossRefPubMedPubMedCentral

51.

Ullmannova V, Popescu NC. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol. 2006;29(5):1127–32.PubMed

52.

Miyagi T, Sato K, Hata K, Taniguchi S. Metastatic potential of transformed rat 3Y1 cell lines is inversely correlated with lysosomal-type sialidase activity. FEBS Lett. 1994;349(2):255–9.CrossRefPubMed

53.

Sawada M, Moriya S, Saito S, Shineha R, Satomi S, Yamori T, et al. Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression. Int J Cancer. 2002;97(2):180–5.CrossRefPubMed

54.

Kato T, Wang Y, Yamaguchi K, Milner CM, Shineha R, Satomi S, et al. Overexpression of lysosomal-type sialidase leads to suppression of metastasis associated with reversion of malignant phenotype in murine B16 melanoma cells. Int J Cancer. 2001;92(6):797–804. doi:10.1002/ijc.1268.CrossRefPubMed

55.

Uemura T, Shiozaki K, Yamaguchi K, Miyazaki S, Satomi S, Kato K, et al. Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4. Oncogene. 2009;28(9):1218–29. doi:10.1038/onc.2008.471.CrossRefPubMed

Title: MicroRNA-125b promotes invasion and metastasis of gastric cancer by targeting STARD13 and NEU1
Authors: Shuai Chang
Shicai He
Guanglin Qiu
Jing Lu
Jin Wang
Junsong Liu
Lin Fan
Wei Zhao
Xiangming Che
Publication date: 01-09-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5094-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2016

Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells

PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc

Construction of random tumor transcriptome expression library for creating and selecting novel tumor antigens

High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer

Erratum to: Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma

Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer